Integrum receives MDR certificate for the OPRA Implant System
Mölndal, Sweden, March 2nd, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announced that the company has received an EU Medical Device Regulation (MDR) certificate for the OPRATM Implant System. With this, the company is provided continued freedom of operation to commercialize its products within the EU.
“We are happy to have passed the strict validation process to receive an MDR certificate. Based on this accomplishment, we can direct our sole focus on the commercial success of the OPRATM Implant System through increased marketing activities and continued clinical evaluation,” comments Rickard Brånemark, CEO of Integrum.
To meet the rigorous demands set by the new regulations, Integrum has worked efficiently over the last years to ensure compliance for both the Quality Management System (QMS) and the technical documentation for the OPRATM Implant System product assortment. This work included an enhancement of the QMS as well as a thorough review and restructuring of the full technical documentation to meet the requirements imposed by MDR. In addition, a review of the clinical evidence and claims of the OPRATM Implant System has been made. OPRATM Implant System will continue to be offered for three amputation levels in Europe.
Collectively, Integrum has invested approximately SEK 40 million, resulting in improved quality management and technical documentation systems that will play a pivotal role in the continued scale-up of the company.
About MDR
In May 2017, the Regulation on Medical Devices (MDR), formulated by the European Commission (EC), went into effect to replace former legislation concerning quality assessment and risk management in medical devices. The new quality and transparency requirements apply to all medical device companies operating within the European Union (EU). The awarded certificate thereby acknowledges that Integrum fulfills the standards set by the MDR, and provides the company continued freedom to commercialize its medical devices in the EU.
For more information please contact:
Rickard Brånemark, CEO. Phone: +46 708 461061, E-mail: rickard.branemark@integrum.se
Dennis Baecklund, CFO. Phone: +46 725 566869, E-mail: dennis.baecklund@integrum.se
Certified Adviser
Erik Penser Bank is Certified Adviser and can be reached at +46 (0) 8-463 8000.
Integrum AB is a publicly traded company (INTEG B: Nasdaq First North exchange) based outside of Gothenburg, Sweden, with a US subsidiary in San Francisco, CA. Since 1990, osseointegration, the science behind the OPRA™ Implant System, has been helping individuals with amputations enjoy a dramatically improved quality of life. Thorough surgical experience gained over more than three decades, from more than 500 surgeries, in 14 countries, has led to the development of Integrum’s system for bone-anchored prostheses – a vastly superior alternative to the traditionally used socket prosthesis.